Pablo R Brumovsky

Dr. Pablo R Brumovsky

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Pain
Verified
Journal Article
Closed access
PBPablo R Brumovsky
Pablo R Brumovsky
Tyrosine hydroxylase (TH) is a rate-limiting enzyme broadly expressed in noradrenergic and dopaminergic neurons in the central nervous system [57,70]. TH is also expressed by peripheral sympathetic neurons [98] as well as by enteric neurons within the gut [81,84]. Over 30 years ago, TH was unexpectedly discovered in developing and adult rodent cranial and dorsal root ganglion (DRG) neurons. Today, TH-expressing DRG neurons are being re-discovered as a relevant subpopulation. This review addresses the emerging importance of TH-expressing DRG neurons in sensation and pain mechanisms, focusing specifically on: 1) their nature as C-low threshold mechanoreceptors (C-LTMRs); 2) their involvement in nociception/pain; and 3) their catecholaminergic phenotype.

2 December 2015 in Biomolecules
Verified
Journal Article
Open access
PDF file
MMMariana Malet
Mariana Malet
PBPablo R Brumovsky
Pablo R Brumovsky
The amino acid glutamate is the principal excitatory transmitter in the nervous system, including in sensory neurons that convey pain sensation from the periphery to the brain. It is now well established that a family of membrane proteins, termed vesicular glutamate transporters (VGLUTs), serve a critical function in these neurons: they incorporate glutamate into synaptic vesicles. VGLUTs have a central role both under normal neurotransmission and pathological conditions, such as neuropathic or inflammatory pain. In the present short review, we will address VGLUTs in the context of primary afferent neurons. We will focus on the role of VGLUTs in pain triggered by noxious stimuli, peripheral nerve injury, and tissue inflammation, as mostly explored in transgenic mice. The possible interplay between glutamate biosynthesis and VGLUT-dependent packaging in synaptic vesicles, and its potential impact in various pain states will be presented.

1 April 2009 in Neuropeptides
Verified
Journal Article
Open access
MCM.F. Coronel
M.F. Coronel
PMP.L. Musolino
P.L. Musolino
PBPablo R Brumovsky
Pablo R Brumovsky
THT. Hökfelt
T. Hökfelt
MVM.J. Villar
M.J. Villar
Single ligature nerve constriction (SLNC) of the rat sciatic nerve triggers neuropathic pain-related behaviors and induces changes in neuropeptide expression in primary afferent neurons. Bone marrow stromal cells (MSCs) injected into the lumbar 4 (L4) dorsal root ganglia (DRGs) of animals subjected to a sciatic nerve SLNC selectively migrate to the other ipsilateral lumbar DRGs (L3, L5 and L6) and prevent mechanical and thermal allodynia. In this study, we have evaluated the effect of MSC administration on the expression of the neuropeptides galanin and NPY, as well as the NPY Y(1)-receptor (Y(1)R) in DRG neurons. Animals were subjected to a sciatic nerve SLNC either alone or followed by the administration of MSCs, phosphate-buffered saline (PBS) or bone marrow non-adherent mononuclear cells (BNMCs), directly into the ipsilateral L4 DRG. Seven days after injury, the ipsilateral and contralateral L4-5 DRGs were dissected out and processed for standard immunohistochemistry, using specific antibodies. As previously reported, SLNC induced an ipsilateral increase in the number of galanin and NPY immunoreactive neurons and a decrease in Y(1)R-positive DRG neurons. The intraganglionic injection of PBS or BNMCs did not modify this pattern of expression. In contrast, MSC administration partially prevented the injury-induced changes in galanin, NPY and Y(1)R expression. The large number of Y(1)R-immunoreactive neurons together with high levels of NPY expression in animals injected with MSCs could explain, at least in part, the analgesic effects exerted by these cells. Our results support MSC participation in the modulation of neuropathic pain and give insight into one of the possible mechanisms involved.

1 June 2017 in Peptides
Verified
Journal Article
Closed access
MMMariana Malet
Mariana Malet
CLCandelaria Leiguarda
Candelaria Leiguarda
GGGuillermo Gastón
Guillermo Gastón
CMCarly McCarthy
Carly McCarthy
PBPablo R Brumovsky
Pablo R Brumovsky

21 November 2020 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
CLCandelaria Leiguarda
Candelaria Leiguarda
CPConstanza Potilinski
Constanza Potilinski
JRJulia Rubione
Julia Rubione
PTPablo Tate
Pablo Tate
MVMarcelo J. Villar
Marcelo J. Villar
PBPablo R Brumovsky
Pablo R Brumovsky

15 September 2021 in Pain
Verified
Journal Article
Closed access
MCMailín Casadei
Mailín Casadei
EFEsteban Fiore
Esteban Fiore
JRJulia Rubione
Julia Rubione
LDLuciana María Domínguez
Luciana María Domínguez
MCMaría Florencia Coronel
María Florencia Coronel
PBPablo R Brumovsky
Pablo R Brumovsky
IMT504, a noncoding, non-CpG oligodeoxynucleotide, modulates pain-like behavior in rats undergoing peripheral nerve injury, through mechanisms that remain poorly characterized. Here, we chose the spared nerve injury model in rats to analyze the contribution of mesenchymal stem cells (MSCs) in the mechanisms of action of IMT504. We show that a single subcutaneous administration of IMT504 reverses mechanical and cold allodynia for at least 5 weeks posttreatment. This event correlated with long-lasting increases in the percentage of MSCs in peripheral blood and injured sciatic nerves, in a process seemingly influenced by modifications in the CXCL12-CXCR4 axis. Also, injured nerves presented with reduced tumor necrosis factor-α and interleukin-1β and increased transforming growth factor-β1 and interleukin-10 protein levels. In vitro analysis of IMT504-pretreated rat or human MSCs revealed internalized oligodeoxynucleotide and confirmed its promigratory effects. Moreover, IMT504-pretreatment induced transcript expression of Tgf-β1 and Il-10 in MSCs; the increase in Il-10 becoming more robust after exposure to injured nerves. Ex vivo exposure of injured nerves to IMT504-pretreated MSCs confirmed the proinflammatory to anti-inflammatory switch observed in vivo. Interestingly, the sole exposure of injured nerves to IMT504 also resulted in downregulated Tnf-α and Il-1β transcripts. Altogether, we reveal for the first time a direct association between the antiallodynic actions of IMT504, its promigratory and cytokine secretion modulating effects on MSCs, and further anti-inflammatory actions at injured nerves. The recapitulation of key outcomes in human MSCs supports the translational potential of IMT504 as a novel treatment for neuropathic pain with a unique mechanism of action involving the regulation of neuroimmune interactions.